{
  "id": 19786135,
  "title": "Citizens maintains Sagimet stock rating on acne pivot confidence",
  "url": "https://urgent.news/2026/11/13/citizens-maintains-sagimet-stock-rating-on-acne-pivot-confidence",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T09:20:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/citizens-maintains-sagimet-stock-rating-on-acne-pivot-confidence-93CH-5024583"
  },
  "original_language": "en",
  "account": "Citizens has maintained a Market Outperform rating and $27.00 price target on Sagimet Biosciences Inc (NASDAQ:SGMT), citing confidence in the company's strategic shift towards acne treatments. The stock has risen 85% year-to-date, reaching $10.93 and nearing its 52-week high of $11.45. The firm's analyst highlighted the potential of denifanstat in acne treatment, noting the high probability of success for the AURORA trial, which evaluates the same denifanstat dose in a larger patient population with similar endpoints. Citizens forecasts Phase 3 data will be available soon, and expects Phase 2 data from the next-generation FASN inhibitor TVB-3567 next year, seeing TVB-3567 as an upside to its valuation. Despite the company's unprofitability and $775 million market cap, InvestorsPro Tips point to its strong balance sheet, with more cash than debt. Oppenheimer and Guggenheim recently raised their price targets for Sagimet Biosciences Inc, while Cantor Fitzgerald reiterated its Overweight rating. Citizens reduced its price target to $27 from $29 and noted that Ascletis' Phase 3 results lessen risks for Sagimet's U.S. Phase 3 AURORA trial. H.C. Wainwright maintained a Buy rating with a $29 price target, viewing an upcoming EADV presentation as a potential catalyst for denifanstat.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}